AU2080201A - Treatment of addiction disorders - Google Patents
Treatment of addiction disordersInfo
- Publication number
- AU2080201A AU2080201A AU20802/01A AU2080201A AU2080201A AU 2080201 A AU2080201 A AU 2080201A AU 20802/01 A AU20802/01 A AU 20802/01A AU 2080201 A AU2080201 A AU 2080201A AU 2080201 A AU2080201 A AU 2080201A
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- addiction disorders
- addiction
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17010499P | 1999-12-10 | 1999-12-10 | |
US60170104 | 1999-12-10 | ||
PCT/US2000/033444 WO2001041763A1 (en) | 1999-12-10 | 2000-12-08 | Treatment of addiction disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2080201A true AU2080201A (en) | 2001-06-18 |
Family
ID=22618564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU20802/01A Abandoned AU2080201A (en) | 1999-12-10 | 2000-12-08 | Treatment of addiction disorders |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2080201A (en) |
WO (1) | WO2001041763A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1685838A1 (en) * | 2000-08-16 | 2006-08-02 | Pharmacia & Upjohn Company LLC | Compounds for the treatment of addictive disorders |
DE10137162A1 (en) * | 2001-07-30 | 2003-02-20 | Hexal Ag | Transdermal therapeutic system for administration of pramipexole or ropinirole for treating Parkinson's disease, comprises backing layer, reservoir, semipermeable membrane, adhesive layer and protecting layer |
DE10148233A1 (en) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Compounds to reduce excessive food intake |
SI21351A (en) * | 2002-12-17 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Treatment of dependence on psychostimulants |
DE10312809A1 (en) * | 2003-03-21 | 2004-09-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pramipexole to reduce excessive food intake in children |
JP2007518754A (en) * | 2004-01-22 | 2007-07-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical composition comprising a monoamine neurotransmitter reuptake inhibitor and a dopamine agonist |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
-
2000
- 2000-12-08 AU AU20802/01A patent/AU2080201A/en not_active Abandoned
- 2000-12-08 WO PCT/US2000/033444 patent/WO2001041763A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001041763A1 (en) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002348135A1 (en) | Methods for the treatment of addiction | |
HUP0400914A3 (en) | Methods of treatment of mitochondrial disorders | |
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
AU3791601A (en) | Treatment of coal | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU1356201A (en) | Treatment of hyperproliferative disorders | |
AUPR074500A0 (en) | Treatment of t cell disorders | |
AU5908300A (en) | Prevention and treatment of amyloid-associated disorders | |
AU3896900A (en) | Treatment of pain | |
AU2001239510A1 (en) | Treatment of renal disorders | |
GB9926968D0 (en) | Treatment of neurological disorders | |
AU5547000A (en) | Novel treatment | |
AU7106300A (en) | Treatment of skin disorders | |
AU7750100A (en) | Method for the treatment of obesity | |
AU2080201A (en) | Treatment of addiction disorders | |
AU4556800A (en) | Novel treatment | |
AU3899100A (en) | Treatment of hyperactivity disorders | |
AU2566201A (en) | Compounds and methods for the treatment of pain | |
AU1405001A (en) | Treatment of diseases | |
AU5646300A (en) | Methods of stimulating angiogenesis | |
AU3753500A (en) | Methods of treating fibrinogen-related disorders | |
AU4598400A (en) | Method of treatment | |
AU2382601A (en) | Novel method of treatment | |
AU2001253560A1 (en) | Methods of treatment | |
AU2420201A (en) | Compounds and methods for the treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |